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epidemiological study, and will be used to test the validity of 
a predictive risk model based on values of neutron RBE which 
will be derived from the physics task in the ANDANTE project. 
Based on the experience from the feasibility study at LLUMC, 
a proposal for a prospective epidemiological study using 
pediatric proton therapy data collected from multiple proton 
centers world-wide is prepared. For this purpose, published 
results of epidemiological studies on second malignant 
neoplasms (SMN) after radiotherapy in childhood are 
reviewed. Up to now, 57 papers were identified from 2001 
until present with the objective to estimate the magnitude of 
the effect of radiation exposure on the occurrence of SMN. 
Furthermore, European proton therapy centers were 
contacted in order to assess the feasibility of creating a 
prospective database on pediatric patients. Five out of 
thirteen proton therapy centers already replied, showing 
great interest in preliminary participation in discussion on 
forming a future prospective study. 
 
Conclusion: This will be essential for investigating the far 
reaching goal to enhance our understanding of the link 
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Purpose or Objective: To: (1) produce a descriptive study of 
Irish children referred abroad for proton therapy (PT), and 
(2) to discuss the case for PT in general.  
 
Material and Methods: A retrospective review of all children 
referred for PT before October 2015 was performed. 
Information was gathered regarding general demographics, 
diagnosis, tumour grade, other treatments, the PT referral 
timeline, relapse where relevant, side effects attributable to 
PT, current status and cost of treatment to the Irish state. 
Additionally, a review of the relevant literature was 
performed. 
 
Results: Sixteen children treated in Ireland have been 
referred abroad for PT to date, with numbers increasing 
yearly. The largest number referred was in the 0–4 year old 
group. At initial diagnosis the median age was 5.0 years. Four 
patients were referred for treatment of rhabdomyosarcoma, 
3 for craniopharyngioma, 6 for intracranial ependymoma and 
1 each for treatment of meningioma, germinoma and ATRT. 
The average cost per child has been approximately €52,000. 
Two patients suffered relapse of their disease - 1 has proven 
fatal and the other is alive with disease. Four patients have 
encountered PT-related adverse effects. The time from 
referral to treatment has improved from 11 to 6 weeks 
approx.  
 
Conclusion: Despite the fact that >100,000 patients 
worldwide have been treated with PT, the current level of 
published evidence to support superiority over conventional 
treatment remains low. Planning studies have clearly 
demonstrated superior conformality and reduced risk to 
normal tissues. It is debated that randomised control trials in 
this area would be inconsistent with the principle of clinical 
equipoise. In contrast, there is a call for level 1 evidence to 
justify such drastic changes in patient care, particularly in 
the light of recent reports of unexpected toxicities.If PT 
were more widely available, the question remains in which 
clinical situations would it be likely to show substantial 
clinical and cost benefit? As no firm conclusions can be 
derived from the literature, the answer is somewhat 
speculative. In time, careful evaluation, follow-up and 
clinical trials will likely support the argument for the 
preferential use of proton therapy in children. Our challenge 
remains: how best to use it in the meantime? 
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Purpose or Objective: In the multimodal treatment concept 
for pediatric tumors the implementation of radiotherapy with 
protons gains more and more importance due to their 
outstanding radiobiological, physical and technical 
characteristics. In particular the fact, that about 60% of the 
irradiated volume of conventional radiotherapy are not 
burdened by proton therapy, results in a considerable 
reduced incidence of side effects with lowering the negative 
impact on growth and development and a lower rate of 
secondary malignancies. The German Society for Radiation 
Oncology (DEGRO) clearly recommends preferably proton 
therapy in the treatment of pediatric patients. 
 
Material and Methods: Analysis of children and adolescents 
undergoing proton radiation therapy since start of the RPTC 
2009 (time period from Jun 2009 to Sep 2015). A highly 
complex three-dimensional electromagnetic proton beam 
control system (spot scanning) can applies the tumor dose 
only to the planned target volume and spares surrounding 
healthy tissue without significant neutron exposure to the 
whole body. There is a wide range of free variety of dose 
intensity to each spot. 
 
Results: From 06/2009 to 07/2015 a total of 82 patients were 
previously treated at the RPTC in 88 cases. The mean age at 
start of irradiation was arithmetically 7.9 years (min. 11mo.; 
max. 17y. 7mo.). These were mostly rhabdomyosarcomas 
(RMS; n = 26 [29.5%]), of which 10 were alveolar and 16 were 
embryonal RMS. In the field of central nervous system, 14 
patients with low grade gliomas [16%], 11 high grade gliomas 
[12.5%], 10 ependymomas [11%] and 2 medulloblastomas 
were treated. From 12 cases with rare tumor types, 8 were 
also localized in the CNS. 6 patients had chordoma and 
chondrosarcoma, 5 Ewing tumors and 2 rare types of soft 
tissue sarcomas. 
 
Conclusion: At the field of pediatric oncology radiotherapy 
with protons using spot scanning technology is certainly 
feasible and a highly effective treatment method with 
significantly lower toxicity of normal tissue. There is a close 
cooperation with the Children's Hospital of the Municipal 
Hospital Munich/ Hospital of Munich Technical University for 
the integration of multimodal therapy studies or to treat in 
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Purpose or Objective: Despite the increasing availability of 
stereotactic ablative body radiotherapy (SABR) and 
stereotactic radiosurgery (SRS) there remains a lack of 
evidence regarding their indications and role in the 
treatment of recurrent & oligo-metastatic tumours in 
children, teenagers & young adults (TYA). 
 
Material and Methods: A retrospective review of paediatric 
and TYA patients (age ≤24 years) treated with SRS or SABR at 
The Royal Marsden Hospital from 2010 to 2015 was 
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performed. Data collected included: tumour type, technique, 
dose, number of fractions, prescription isodose, acute and 
late toxicity (CTCAE v4.0), local control (LC) and progression 
free survival (PFS). 
 
Results: 12 patients were identified: 8 males and 4 females; 
median age 14.5 years [5-20 years]. Cranial SRS was delivered 
to 9 sites in 7 patients, and extracranial SABR was delivered 
to 8 sites in 5 patients. All patients had a Lansky/ Karnofsky 
score ≥70. All SABR and SRS treatments were performed using 
the Cyberknife® platform; 8 treatments prescribed as a 
single fraction (median dose 19 [18-24] Gy), 4 treatments 
were given in 3 fractions (median dose 28.5 [27-42]Gy) and 5 
treatments in 5 fractions (median dose 30 [30-35]Gy). The 
median prescribing isodose was 79% [70-81%]. For 5 patients 
SRS was delivered post surgical resection with no 
macroscopical residual disease at the time of treatment. The 
treatment for 9 (75%) patients was to previously irradiated 
sites. After a median follow up of 14.5 [0.9-36.2] months 9 
pts (75%) were alive, 2 died from disease progression and 1 
died from unclear cause. MRI response assessment was 
performed at a mean time of 6 [3-17] weeks; 1 patient had a 
complete response, 10 had stable disease (83 %); 1 was not 
assessed due to a rapid clinical deterioration. LC was 100 % 
and 85.7% at 1 and 2 years respectively. PFS was 82.5% at 1 
year and 61.9 % at 2 years. 3 reirradiated patients reported 
symptomatic grade 3 radionecrosis, requiring medical 
therapy. 
 
Conclusion: In this cohort, SABR and SRS with Cyberknife® 
have proven feasible in the subset of paediatric & TYA 
patients with recurrent or oligo-metastatic tumours. It 
achieved good local control even in pre-irradiated patients. 
However optimal patient selection for such a treatment 
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Purpose or Objective: Particle therapy is not available in our 
country yet, however, quite a few patients are sent abroad 
for such therapy. In the largest health trust, covering a 
population of 2.9 million, 25-40 pediatric patients (< 18 
years) are treated with radiotherapy (RT) yearly. We wanted 
to analyze this group of patient with respect to RT technique 
and diagnosis. 
 
Material and Methods: All pediatric patients treated 
between January 2006 and June 2015 were identified and 
included. The treatment techniques were categorized as 
follows: total body irradiation (TBI), whole CNS RT, 
IMRT/VMAT, stereotactic RT (SRT), 3D conformal RT (CRT), 
kV RT and extracorporal irradiation (ExCRT). Additionally, 
the pediatric patients referred for proton RT abroad were 
registered. 
 
Results: 302 pediatric patients were treated with RT in the 
period. The mean age at treatment were 11.3 ± 4.6 years. 69 
patients (25%) had brain tumors, whereas 50 (18%) and 43 
(16%) patients were diagnosed with lymphoma and leukemia, 
respectively.  
The figure gives the distribution of the treatment techniques 
trough the whole period (upper panel), showing that more 
than 50 % of the patients have been treated with CRT. The 
lower panel in the figure shows the distribution in 2006 (left) 
and 2014 (right), indicating that the proportion of patients 
receiving CRT has decreased from 50 to 38 %. However, the 
number of patients only reduced from 18 in 2006 to 15 in 
2014. The number of patients treated with advanced 
techniques (IMRT/VMAT, SRT) did not change significantly. 
On the other hand, 20 % of the patients were referred for 
proton RT abroad in 2014, while no one received such 
treatment in 2006. The number of patients where the whole 
CNS were treated reduced from 8 (25%) in 2006 to 3 (8%) in 
2014.  
In the whole period 31 patients (10%) were treated with TBI 
and the number of patients per year did not changed 




Conclusion: An official agreement was established with 
proton centers abroad in 2013. The reduction in whole CNS 
treatment throughout the period is due to this agreement. 
Except TBI, kV RT and ExCRT, all the other techniques should 
be replaced with proton RT when such treatment becomes 
available. 
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Purpose or Objective: The Norwegian Breast Cancer Group 
provides national guidelines regarding systemic therapy for 
metastatic breast cancer. While our center adheres to these 
recommendations, use of palliative radiotherapy (PRT) for 
bone metastases is less standardized. Despite general 
recommendations for short course PRT for uncomplicated 
metastases, many physicians prefer ≥10 fractions (long 
course, LC). Our aim was to analyze factors associated with 
prescription of ≥10 fractions. 
 
Material and Methods: This retrospective study included 118 
female patients (all received systemic therapy including 
bone-targeting agents in accordance with national 
guidelines). 
 
Results: Median age was 61 years, and median survival 13 
months. Long-course PRT was prescribed in 60% of patients, 
while 21% had PRT with 8 Gy single fraction to at least one 
target. Reirradiation rate was numerically higher after 8 Gy 
(9%, compared to 5% after LC PRT and 6% after 4 Gy x5, not 
significant). Patients with favorable baseline characteristics 
were significantly more likely to receive LC PRT. These 
characteristics included absence of lung metastases and/or 
